Alphatec

Key Findings

• Economic: EOS imaging, wholly acquired by Alphatec in 2021, has a documented Israeli equipment-service channel involving BesTech Ltd. Israeli procurement records identify EOS equipment repair at Sheba Medical Center in 2023 and a proposed service agreement at Tel Aviv Sourasky Medical Center in 2026; manufacturer authorisation terms and upstream payments to EOS or Alphatec remain unverified.^{1, 2, 3, 4}
• Political: EOS imaging’s announcement of its first Israeli sale, originally published in April 2017 before Alphatec’s acquisition, remained publicly retrievable in October 2026. The audits do not establish republication, a contemporary promotional campaign, or a new Alphatec political endorsement.^{5, 6}
• Not found: No public evidence identified of Israeli military procurement, military targeting applications, security-sector digital provision, or settlement-specific operations. The documented products and named Israeli customers concern civilian medical imaging and spinal care.^{7, 5, 3, 4, 8, 9}

Target Profile

Executive Summary

Alphatec develops medical technologies for spinal disorders through Alphatec Spine, SafeOp Surgical, and EOS imaging. Its documented Israel nexus centres on EOS medical imaging equipment and related hospital services. EOS announced its first Israeli sale to Tel Aviv Sourasky Medical Center on 5 April 2017, with installation expected at Dana-Dwek Hospital that month. That transaction preceded Alphatec’s acquisition: Alphatec obtained control of EOS in May 2021 and full ownership in June 2021.^{7, 1, 5}

The strongest economic evidence extends beyond the historical sale. BesTech publicly lists EOS imaging among its “Exclusive Partners,” while Israeli Ministry of Health procurement records identify BesTech Ltd, company number 514338664, as the supplier for EOS equipment repair at Sheba Medical Center and proposed servicing at Sourasky. The Sheba record specifies ₪400,000 for a stated November 2023–November 2025 engagement; the Sourasky notice specifies €300,546 including VAT for a proposed July 2026–July 2029 service period. These records support an active Israeli EOS equipment-service channel after Alphatec’s acquisition, while leaving the manufacturer’s contractual participation and remuneration unverified.^{2, 3, 4}

The political audit’s affirmative record is narrower: the original 2017 Israeli-sale announcement remained publicly retrievable on the acquired EOS business’s website in October 2026. Its accessibility does not establish uninterrupted publication, republication in 2026, a current promotional campaign, political endorsement, or renewal of the original transaction. The economic audit supplies later procurement evidence, but the 2026 Sourasky agreement’s execution, final approval, paid-service commencement, and settlement of payments remain unresolved.^{5, 6, 4, 13}

No public evidence identified of Israeli defence contracts, weapons or targeting systems, intelligence technology provision, settlement-specific operations, Israel-related political donations, or corporate lobbying on the conflict. The documentary record identifies civilian medical functions and hospital customers. The fixed, human-vetted V6.6 result is BRS 306, Tier D (Moderate Complicity), with Military and Digital both zero; that corpus classification must be read alongside the substantial attribution, contractual, and financial limits described below.^{7, 11, 5, 3, 4, 12, 8, 9}

Timeline of Relevant Events

Corporate Overview

Alphatec Holdings is a Delaware-incorporated, publicly traded medical-technology holding company headquartered in Carlsbad. Its identified wholly owned operating subsidiaries are Alphatec Spine, SafeOp Surgical, and EOS imaging. The group’s disclosed activities concern spinal implants, surgical techniques, neurological monitoring, medical imaging, and clinical planning systems.^{7, 11}

SafeOp entered the group in 2018. EOS became wholly owned in June 2021, following a controlling acquisition in May. Consequently, EOS’s 2017 Israeli sale and the 2018 Sheba equipment procurement predate Alphatec ownership; the 2023 and 2026 procurement records fall within the subsequent ownership period. This distinction establishes the relevant corporate chronology without attributing pre-acquisition negotiations to Alphatec.^{1, 5, 3, 4, 15, 16}

BesTech is the named Israeli intermediary in the later evidence. Its public partnership page and hospital procurement records support a commercial equipment-service relationship involving EOS products. They do not establish BesTech as an Alphatec subsidiary or franchisee, disclose an executed manufacturer agreement, or independently verify the scope of its claimed exclusivity. No public evidence identified of an Alphatec-owned Israeli operating subsidiary, office, manufacturing site, payroll operation, or research centre.^{7, 2, 3, 4}

Ownership and governance records identify several institutional and management shareholders, including BlackRock, Squadron-related entities, Patrick Miles, and David Pelizzon. The existence of these holdings does not attribute shareholders’ other investments or activities to Alphatec. No public evidence identified of Israeli beneficial control or an Israeli state ownership mandate.¹²

Domain Summaries

Military: Military

Mechanism of Involvement

No public evidence identified of a qualifying Israeli military mechanism. The military audit found no contract, procurement award, equipment-supply arrangement, or military partnership involving Alphatec’s identified group and Israeli defence or security bodies. Its affirmative corporate evidence describes a surgical medical-technology business.^{7, 11}

The identified technologies have clinical functions. SafeOp monitors neurological function during surgery; EOS Insight combines medical imaging, AI-assisted measurements, surgical planning, and postoperative analysis. No public evidence identified of military-specific variants, kinetic targeting, fire control, weapons guidance, kill-chain automation, or Israeli military end-user certification.^{8, 9, 20}

The audit also identified no supply of weapons, munitions, critical military subsystems, heavy construction machinery, military logistics, or base services. No public evidence identified of component supply to an Israeli defence prime or equipment involvement in settlement construction, demolition, checkpoints, or military installations.^{7, 11}

Counter-Arguments and Evidence Limits

The company’s strongest defence is the documented civilian nature of its products and customers, together with the absence of identified Israeli defence contracts. A clinical imaging sale to a civilian hospital does not establish military procurement. Nor does AI-assisted medical planning establish military targeting functionality.^{5, 8, 9}

The second-quarter 2026 filing records inventory purchases from a Squadron Capital affiliate: $5.8 million for the quarter and $11.4 million for the six-month period. It also identifies director David Pelizzon’s Squadron relationship. Those disclosures establish related-party commercial purchases; they do not identify military inventory or an Israeli defence end-user.¹¹

The 2016 sale of international distribution operations cannot establish continuing Alphatec control over the former network. The associated supply agreement ended in August 2021. Similarly, the separate Israeli aesthetic-medicine business called ALPHA TEC is not established as an Alphatec Holdings subsidiary, distributor, licensee, or controlled affiliate.^{1, 14, 21}

Named Entities and Evidence Map

Digital: Digital

Mechanism of Involvement

No public evidence identified of a qualifying Israeli digital-security nexus. Alphatec operates substantial clinical technology, including cloud-based EOS Insight and SafeOp neuromonitoring, but the audits do not establish Israeli military, intelligence, surveillance, sovereign-cloud, or settlement-specific digital provision.^{8, 9, 20}

EOS Insight processes patient-specific imaging measurements and supports planning and outcome assessment. Its disclosed initial implementation was in the United States. The historical 2017 Israeli EOS equipment sale does not independently establish deployment of EOS Insight, current transmission of Israeli patient data to Alphatec-controlled cloud systems, or Israeli hosting of global clinical data.^{5, 8, 9}

No public evidence identified of Israeli-origin enterprise cybersecurity dependency, Israeli data-centre operations, Project Nimbus participation, offensive cyber capabilities, security biometrics, or military datasets used for Alphatec model training.^{7, 8, 9}

Counter-Arguments and Evidence Limits

The strongest defence is the distinction between clinical information processing and security technology. Neurological signals, anatomical measurements, patient-specific models, and surgical analytics are documented medical applications. The audits found no evidence connecting these functions to Israeli surveillance, intelligence collection, or targeting.^{8, 9, 20}

Hosting locations, backup infrastructure, cloud processors, and training-data geography were not established by the reviewed product descriptions. These are unresolved technical details; they do not support an inference of Israeli processing or state access.⁹

The later economic evidence establishes EOS equipment repair and proposed maintenance procurement. It does not identify an EOS Insight cloud contract, patient-data arrangement, or security-sector application. Accordingly, an equipment-service channel cannot be converted into a digital-security finding.^{3, 4}

Named Entities and Evidence Map

Economic: Economic

Mechanism of Involvement

The affirmative economic mechanism is a civilian medical-equipment and service channel through acquired subsidiary EOS imaging. The 2017 Sourasky sale establishes the historical customer relationship. BesTech’s partnership disclosure and official procurement notices provide stronger, later evidence of Israeli institutional EOS equipment support after the 2021 acquisition.^{1, 5, 2, 3, 4}

The supplier chronology spans the acquisition. A 2018 Sheba notice names BesTech for an EOS spinal and limb imaging device valued at ₪3,741,566. The later Sheba repair procedure names the same legal entity, specifies ₪400,000, and gives a November 2023–November 2025 engagement period. The November and December 2023 publications concern one procedure and must not be counted as separate transactions.^{3, 16, 18}

Sourasky’s 2026 notice describes a proposed service agreement with BesTech for 14 July 2026–14 July 2029, valued at €300,546 including VAT, with an option to increase or decrease scope by up to 100%. It invokes the single-supplier exemption under Regulation 3(29). This establishes a post-November 2024 procurement process and continuing institutional demand for EOS-related services.⁴

The economic audit’s later procurement findings qualify earlier passages reporting no identified current distributor or post-2024 relationship. The synthesis supports a publicly represented partnership and documented service channel; it does not establish a completed manufacturer sale or payment to Alphatec.^{2, 3, 4, 13}

Counter-Arguments and Evidence Limits

The strongest defence combines civilian purpose, intermediary attribution, and uncertain financial benefit. The hospitals procure services from BesTech. The reviewed records do not establish whether EOS supplies spare parts, warranties, software, technical support, licences, or revenue-sharing arrangements for those engagements. No quantified upstream benefit to EOS or Alphatec can be derived from the hospital procurement values.^{2, 3, 4, 13}

The Sourasky notice does not conclusively establish a signed agreement, final approval, commencement of paid services, or completed settlement. The independent Open Budget entry reported that a committee decision had not been received in its dataset. Its shekel display also conflicts with the official notice’s euro denomination; the dossier follows the original notice’s €300,546 figure.^{4, 13}

BesTech’s “Exclusive Partner” description is its own public representation. Manufacturer authorisation, territorial coverage, product restrictions, margins, purchasing obligations, and termination provisions remain unverified. No public evidence identified of settlement sourcing, settlement-derived revenue, Israeli direct investment, Israeli state financing, or an Israeli-controlled parent.^{7, 2, 12}

Named Entities and Evidence Map

Political: Political

Mechanism of Involvement

The political audit’s documented affirmative nexus is inherited commercial publicity: EOS’s original April 2017 announcement of its first Israeli sale remained retrievable in October 2026, while the current EOS website identified the business as part of the ATEC Spine Group. The original announcement framed the transaction as medical innovation and international market expansion.^{5, 6}

That observation establishes accessibility of historical corporate material within an acquired subsidiary’s web presence. It does not establish a new political statement, uninterrupted availability during every intervening year, verified audience reach, or a contemporary promotional campaign. No public evidence identified of a current navigation link expressly promoting the historical sale.^{5, 6}

The economic procurement records add evidence of later civilian institutional activity. They do not establish political advocacy, military support, or settlement operations. No public evidence identified of corporate endorsements of military action, Israel-related lobbying, anti-BDS campaigning, settlement sponsorship, or donations to Israeli military-support organisations.^{3, 4, 12}

Counter-Arguments and Evidence Limits

The company’s strongest defence is that an accessible historical medical-sales announcement is limited evidence of present political conduct. The sale preceded Alphatec ownership, concerned a civilian hospital, and was described in clinical and commercial terms. No public evidence identified that Alphatec negotiated, financed, renewed, or independently promoted the original transaction after acquisition.^{1, 5, 6}

No public evidence identified of a new post-acquisition political endorsement, conflict-related employee restrictions, Palestine-related censorship, Israel-specific reservist subsidies, or verified principal donations to settlement or military-support organisations. Leadership and shareholder associations do not substitute for attributable conduct.^{12, 8, 19}

The political audit’s absence findings concerning later customer activity must be read alongside the economic audit’s procurement additions. Those additions narrow the commercial uncertainty, but the proposed 2026 contract remains unresolved and neither procurement establishes a political position. No public evidence identified of settlement-specific facilities, customers, tenders, or services.^{3, 4, 13}

Named Entities and Evidence Map

Complicity Index Score

Method: V6.6 - final human-vetted values.

• V_MAX: 3.50 Avg_OTHERS: 0.83
• BRS Score: 306 Tier: D (Moderate Complicity)

Political supplies the fixed V_MAX of 3.50, alongside Economic’s 2.50 and zero military and digital scores; the supplied final result is 306, Tier D. The affirmative record comprises inherited commercial publicity and documented civilian equipment-service activity, subject to the caveats above; no separate reviewed rationale was supplied explaining the precise numerical calibration. These values are retained unchanged under the scale-free, evidence-only, human-vetted method, without treating the tier label as evidence of additional conduct.

Methodology Note

• This dossier synthesises only the four supplied domain audits, with their evidence cutoff of 26 October 2026. It introduces no independently researched allegations.
• Under the supplied scale-free framework, Impact (I) concerns activity type, Magnitude (M) concerns scale, and Proximity (P) concerns directness. The final V6.6 scores are fixed human-vetted inputs.
• Historical conduct is dated and attributed to the entity responsible at the time. Pre-acquisition EOS transactions remain distinguished from Alphatec-era activity; divested operations and terminated arrangements mitigate continuing attribution.
• Entity attribution requires a documented connection. Similar names, shareholder portfolios, professional backgrounds, and banking relationships do not establish transitive corporate responsibility.
• A verified settlement operation would count in both Economic and Political. No public evidence identified of such an operation here.
• “No public evidence identified” reports the audits’ negative findings, rather than proving universal absence. Proposed procurement remains distinguished from execution, and institutional procurement values remain distinguished from verified manufacturer revenue.